Outlook Therapeutics said the FDA approved LYTENAVA, giving the company a key commercial foothold in retinal disease. The drug is the first ophthalmic bevacizum

Outlook Therapeutics said the FDA approved LYTENAVA, giving the company a key commercial foothold in retinal disease. The drug is the first ophthalmic bevacizumab for neovascular AMD, as Outlook also pushes for broader adoption and fresh capital.